Journal for ImmunoTherapy of Cancer · 2014 · 90 citations · 6 references
MedicineOncologyOphthalmologyImmunotherapyMetastasisOcular OncologyCancer ImmunotherapyCutaneous Metastatic DiseaseImmune Checkpoint InhibitorsImmunotherapy For Skin CancerMetastatic Disease TreatmentRetinal Vascular DiseaseComplete Response AssessmentMetastatic Melanoma TreatmentMetastatic Ocular TumorsOcular MetastasisOcular VasculitisPd-1 SignalingPembrolizumab TherapyVitreous Metastasis
We report on a 36-year-old woman treated with the anti PD-1 antibody Pembrolizumab for metastatic cutaneous melanoma in the first line setting. She achieved a complete response and then relapsed with metastases to the vitreous cavity with an associated angiographically determined retinal vasculitis. Vitreous metastasis without choroidal involvement is unusual and may be due to individual cell extravasation, vitreous hemorrhage containing malignant cells, or direct spread through the optic nerve. This finding highlights the need for immune sanctuary sites to be monitored in the presence of PD-1 inhibition and we hypothesize that the use of PD-1 inhibitor potentiated the patient's angiographically determined retinal vasculitis.
6
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Immunology, Oncology +17
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin, Marc S. Ernstoff, Omid Hamid et al. · The Lancet Oncology · 2012 · 1.1K citations
Medicine, Oncology, Pharmacology +12
Melanoma-Associated Retinopathy
Ying Lu · Archives of Ophthalmology · 2009 · 103 citations